🟢 NanoViricides is trading 10.46% up in pre-market after Phase II Ebola trial dosing scheduled next week

NanoViricides is trading $1.33 (+10.46%) after announcing Phase II NV-387 oral-gummy Ebola trial dosing is scheduled next week in the Democratic Republic of Congo.

• The September 15, 2026 announcement said first-patient dosing is expected next week, barring outbreak-related impediments.
• The trial was registered in the Pan African Clinical Trials Registry.
• The catalyst follows a 14.29% gain on September 16; broader markets are firmly higher pre-market, supporting risk appetite, but the trial update is the clearest company-specific catalyst.